BRPI0418232A - formulação inalante contendo éter sulfoalquìlico ciclodextrina e corticosteróide a partir de uma suspensão de dose unitária - Google Patents

formulação inalante contendo éter sulfoalquìlico ciclodextrina e corticosteróide a partir de uma suspensão de dose unitária

Info

Publication number
BRPI0418232A
BRPI0418232A BRPI0418232-4A BRPI0418232A BRPI0418232A BR PI0418232 A BRPI0418232 A BR PI0418232A BR PI0418232 A BRPI0418232 A BR PI0418232A BR PI0418232 A BRPI0418232 A BR PI0418232A
Authority
BR
Brazil
Prior art keywords
formulation
unit dose
corticosteroid
sae
suspension
Prior art date
Application number
BRPI0418232-4A
Other languages
English (en)
Inventor
Rupert O Zimmerer
James D Pipkin
Diane O Thompson
Gerold L Mosher
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Publication of BRPI0418232A publication Critical patent/BRPI0418232A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO INALANTE CONTENDO éTER SULFOALQUìLICO CICLODEXTRINA E CORTICOSTERóIDE PREPARADA A PARTIR DE UMA SUSPENSãO DE DOSE UNITáRIA". A presente invenção refere-se a uma formulação líquida de dose unitária inalável contendo SAE-CD e corticosteróide. A formulação é adaptada para a administração a um paciente por nebulização com qualquer nebulizador conhecido. A formulação pode ser incluída em um kit. A formulação é administrada como uma solução aquosa ou composição concentrada. A formulação é empregada em um sistema de nebulização aperfeiçoado para administrar corticosteróide por inalação. A SAE-CD presente na formulação aumenta significativamente a estabilidade química do corticosteróide, tal como a budesonida. é proporcionado um método de administrar a formulação por inalação. A formulação também pode ser administrada por aparelhagem convencional de distribuição nasal. A formulação é preparada misturando-se a SAE-CD, na forma sólida ou líquida (dissolvida), com uma formulação de dose unitária baseada em suspensão inalável.
BRPI0418232-4A 2003-12-31 2005-01-03 formulação inalante contendo éter sulfoalquìlico ciclodextrina e corticosteróide a partir de uma suspensão de dose unitária BRPI0418232A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53362803P 2003-12-31 2003-12-31
PCT/US2005/000084 WO2005065651A1 (en) 2003-12-31 2005-01-03 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension

Publications (1)

Publication Number Publication Date
BRPI0418232A true BRPI0418232A (pt) 2007-04-27

Family

ID=34794240

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0418276A BRPI0418276B8 (pt) 2003-12-31 2004-12-31 formulação líquida inalável compreeendendo budesonida
BRPI0418386-0A BRPI0418386A (pt) 2003-12-31 2004-12-31 formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide
BRPI0418232-4A BRPI0418232A (pt) 2003-12-31 2005-01-03 formulação inalante contendo éter sulfoalquìlico ciclodextrina e corticosteróide a partir de uma suspensão de dose unitária

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI0418276A BRPI0418276B8 (pt) 2003-12-31 2004-12-31 formulação líquida inalável compreeendendo budesonida
BRPI0418386-0A BRPI0418386A (pt) 2003-12-31 2004-12-31 formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide

Country Status (15)

Country Link
EP (4) EP1729724A4 (pt)
JP (6) JP2007517069A (pt)
KR (3) KR20070007076A (pt)
CN (3) CN1921834A (pt)
AU (3) AU2004312096A1 (pt)
BR (3) BRPI0418276B8 (pt)
CA (3) CA2551826A1 (pt)
DK (1) DK1732512T3 (pt)
HU (1) HUE032527T2 (pt)
IL (6) IL176577A0 (pt)
MX (2) MX348041B (pt)
NZ (1) NZ548225A (pt)
PT (1) PT1732512T (pt)
RU (3) RU2390330C2 (pt)
WO (3) WO2005065435A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MXPA06012240A (es) 2004-04-23 2007-01-31 Cydex Inc Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
MX348982B (es) * 2005-10-26 2017-07-06 Cydex Pharmaceuticals Inc Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
BRPI0618653A2 (pt) * 2005-11-15 2011-09-06 Baxter Int composições compreendendo inibidores da lipoxigenase e ciclodextrina
US20070129329A1 (en) * 2005-12-02 2007-06-07 Alembic Limited Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
WO2007075800A2 (en) * 2005-12-20 2007-07-05 Tika Läkemedel Ab Methods and systems for the delivery of corticosteroids
SI1971369T1 (sl) * 2005-12-21 2009-12-31 Meda Pharma Gmbh & Co Kg Kombinacija R,R-glikopirolata,roliprama in budezonida za zdravljenje vnetnih bolezni
CN101389313A (zh) * 2006-02-10 2009-03-18 帕锐制药两和公司 用于吸入疗法的雾化抗生素
CA2642579A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Sterilization of corticosteroids with reduced mass loss
DK2010220T3 (da) * 2006-04-03 2022-05-23 Ceva Animal Health Pty Ltd Stabiliserede pentosanpolysulfat-(pps)-formuleringer
DK2041158T3 (da) 2006-06-19 2013-06-24 Onyx Therapeutics Inc Peptid-epoxidketoner til proteasom inhibering
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1894559A1 (en) * 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
AU2007311607A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
WO2008065142A1 (en) * 2006-11-29 2008-06-05 N.V. Organon Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
EP3766493B1 (en) 2007-04-27 2023-08-23 CyDex Pharmaceuticals, Inc. Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
MX2010005100A (es) * 2007-11-09 2010-11-12 Map Pharmaceuticals Inc Metodos para administrar formulaciones de corticoesteroides.
WO2010048298A1 (en) 2008-10-21 2010-04-29 Proteolix, Inc. Combination therapy with peptide epoxyketones
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
CN102421451B (zh) * 2009-02-25 2013-11-06 休普拉特克药品有限公司 苯达莫司汀环多糖组合物
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5808739B2 (ja) 2009-05-13 2015-11-10 サイデックス・ファーマシューティカルズ・インコーポレイテッド プラスグレル及びシクロデキストリン誘導体を含む医薬組成物並びにその製造方法及び使用方法
EP2435024B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
EP2442821B1 (en) 2009-06-18 2017-06-14 Allergan, Inc. Safe desmopressin administration
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RU2445119C2 (ru) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Фармацевтическая композиция и способ ее ингаляционного введения
US20140155486A1 (en) * 2011-04-26 2014-06-05 Tobias Gessler Administration of Iloprost as Aerosol Bolus
CN102188371B (zh) * 2011-05-11 2013-01-23 台州职业技术学院 一种环索奈德纳米粒水溶液及其制备方法
CN102973574A (zh) * 2011-09-02 2013-03-20 北京燕锋晨医药技术发展有限公司 一种用于治疗哮喘的药物组合物及制备方法
EP4410374A2 (en) * 2012-05-08 2024-08-07 Onyx Therapeutics, Inc. Cylodextrin complexation methods for formulating peptide proteasome inhibitors
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP3741772B1 (en) 2012-05-08 2024-06-19 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2506080C1 (ru) * 2012-09-25 2014-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО НижГМА Минздравсоцразвития России) Способ лечения и профилактики осложнений в полости рта, вызванных приемом ингаляционных гормональных препаратов у больных бронхиальной астмой
RU2493827C1 (ru) * 2012-10-03 2013-09-27 Шолекс Девелопмент Гмбх Стабильный комбинированный раствор фенотерола гидробромида и ипратропия бромида
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2923702A1 (en) 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
NZ724902A (en) * 2014-03-28 2023-03-31 Univ Liege Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
US20180028440A1 (en) * 2015-02-13 2018-02-01 Vanderbilt University Milrinone Composition and Method for Administering Same
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
WO2017193110A1 (en) * 2016-05-06 2017-11-09 Stites Adam Cannabinoid compositions for sublingual spray nebulizer
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2019147154A1 (ru) * 2018-01-23 2019-08-01 Александр Григорьевич ЧУЧАЛИН Фармацевтическая композиция (варианты) применение фармацевтической композиции (варианты)
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021262648A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol and budesonide
WO2021262675A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
CN113018280A (zh) * 2021-03-01 2021-06-25 石家庄四药有限公司 一种异丙托溴铵吸入用溶液制剂及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008875A (en) * 1960-01-08 1961-11-14 Upjohn Co Neomycin and mirystyl-gamma-picolinium halide compositions
NL289785A (pt) * 1962-11-29
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5510339A (en) 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
EP0865789B1 (en) 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE69530519T2 (de) 1994-12-22 2004-03-04 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
WO1998018827A1 (en) * 1996-10-28 1998-05-07 Farmarc Nederland B.V. Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DK0889056T3 (da) 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
AU2081999A (en) 1998-01-13 1999-08-02 Astrazeneca Uk Limited Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity
NZ505951A (en) 1998-02-23 2003-02-28 Cyclops Ehf A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
FR2789685B1 (fr) 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
DE60117777T2 (de) 2000-05-11 2006-08-17 Eastman Chemical Co., Kingsport Acylierte zyclodextrin guest-inklusion komplexe
JP2005503446A (ja) 2001-01-11 2005-02-03 イーストマン ケミカル カンパニー シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
DE60211132T2 (de) 2001-02-14 2006-09-28 Akzo Nobel N.V. 2-alkylierte cyclodextrin-derivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2501132A1 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto

Also Published As

Publication number Publication date
AU2004312095A1 (en) 2005-07-21
KR20070007075A (ko) 2007-01-12
JP2015129173A (ja) 2015-07-16
DK1732512T3 (en) 2017-07-10
RU2388462C2 (ru) 2010-05-10
CN1921830A (zh) 2007-02-28
PT1732512T (pt) 2017-07-24
JP2007517069A (ja) 2007-06-28
JP2012224648A (ja) 2012-11-15
CN1921834A (zh) 2007-02-28
IL176577A0 (en) 2006-10-31
BRPI0418276B1 (pt) 2017-02-14
JP2007517067A (ja) 2007-06-28
JP2016172774A (ja) 2016-09-29
KR20070005586A (ko) 2007-01-10
CN1976679B (zh) 2011-08-31
EP1729724A1 (en) 2006-12-13
WO2005065435A3 (en) 2005-09-01
WO2005065649A1 (en) 2005-07-21
IL225946A (en) 2017-04-30
JP6186478B2 (ja) 2017-08-23
IL176576A0 (en) 2006-10-31
HUE032527T2 (en) 2017-09-28
NZ548225A (en) 2012-12-21
IL251496A0 (en) 2017-05-29
CA2552641A1 (en) 2005-07-21
WO2005065435A2 (en) 2005-07-21
WO2005065651A1 (en) 2005-07-21
BRPI0418386A (pt) 2007-05-22
EP1732512A2 (en) 2006-12-20
RU2390330C2 (ru) 2010-05-27
RU2006127443A (ru) 2008-02-10
IL176575A0 (en) 2006-10-31
MXPA06007581A (es) 2007-03-09
BRPI0418276A (pt) 2007-05-02
EP1732512B1 (en) 2017-03-22
JP5782413B2 (ja) 2015-09-24
CN1976679A (zh) 2007-06-06
RU2006127432A (ru) 2008-02-10
CA2551826A1 (en) 2005-07-21
EP1729724A4 (en) 2008-07-23
EP1718276A2 (en) 2006-11-08
IL251496B (en) 2021-04-29
IL225946A0 (en) 2013-06-27
JP2007517068A (ja) 2007-06-28
AU2004311478A1 (en) 2005-07-21
CA2551749A1 (en) 2005-07-21
RU2006127467A (ru) 2008-02-10
AU2004312096A1 (en) 2005-07-21
CA2551749C (en) 2014-02-11
EP3238708A1 (en) 2017-11-01
KR20070007076A (ko) 2007-01-12
BRPI0418276B8 (pt) 2021-05-25
MX348041B (es) 2017-05-25
EP1718276A4 (en) 2008-07-23
EP1732512A4 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
BRPI0418232A (pt) formulação inalante contendo éter sulfoalquìlico ciclodextrina e corticosteróide a partir de uma suspensão de dose unitária
WO2008005692A3 (en) INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID
BR0308274A (pt) Formulação de formoterol superfino
KR20010052721A (ko) 급성 천식 질환의 예방 또는 치료를 위한 포르모테롤 및부데소니드를 포함하는 조성물의 용도
CN101606903A (zh) 一种氨溴索的雾化吸入用溶液剂及其制备方法
CA2888428C (en) Ciclesonide for the treatment of airway disease in horses
CN109771398B (zh) 一种帕拉米韦溶液型吸入剂及其制备方法
US20240189348A1 (en) Non-infective nasal symptom management compositions and methods
TW200524615A (en) Aqueous suspensions of ciclesonide for nebulisation
US20210386748A1 (en) Non-infective nasal symptom management compositions and methods
US11826382B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11701426B2 (en) Non-infective nasal symptom management compositions and methods
ES2909039T3 (es) Formulación farmacéutica que comprende ciclesonida
US20220133786A1 (en) THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
JP2023547040A (ja) ピロロピリジン－アニリン化合物による、認知機能不全の処置方法
US20200121696A1 (en) Non-infective nasal symptom management compositions and methods
US20160279057A1 (en) Azelastine Formulations For Intranasal Nebulization And Irrigation
US11642372B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
WO2009032955A1 (en) Dheas inhalation compositions
WO2010025505A1 (en) Analgesia by transmucosal administration
CN112957350A (zh) 一种鱼腥草雾化吸入用溶液制剂及其制备方法
US12042514B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
CN117205186B (zh) 一种雷芬那辛吸入喷雾剂及其制备方法
US20240009161A1 (en) THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
US20240091253A1 (en) THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.